Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor: Novartis Pharmaceuticals
Summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Official title: A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
272
Start Date
2026-03-09
Completion Date
2029-08-22
Last Updated
2026-07-09
Healthy Volunteers
No
Interventions
FWY003
FWY003 arm participants will receive a specific dose of FWY003
Placebo
Placebo arm participants will receive placebo
Locations (51)
Salehi Retina Institute
Huntington Beach, California, United States
Retinal Consultants Medical Group Inc
Sacramento, California, United States
California Retina Consultants
Santa Barbara, California, United States
Advanced Research LLC
Boynton Beach, Florida, United States
Advanced Research LLC
Deerfield Beach, Florida, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
Opthamalic Consultants of Boston
Boston, Massachusetts, United States
NJ Retina
Toms River, New Jersey, United States
New York Eye and Ear Infirmary of Mount Sinai
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Erie Retina Research LLC
Erie, Pennsylvania, United States
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Retina Consultants TX Rsrch Ctr
Bellaire, Texas, United States
Retina Consultants of Houston PA
Houston, Texas, United States
Retina Consultants of Texas
Katy, Texas, United States
Novartis Investigative Site
Albury, New South Wales, Australia
Novartis Investigative Site
Parramatta, New South Wales, Australia
Novartis Investigative Site
Strathfield, New South Wales, Australia
Novartis Investigative Site
East Melbourne, Victoria, Australia
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Lyon, Rhone, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Ludwigshafen, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Pécs, Baranya, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Novartis Investigative Site
Krakow, Poland
Emanuelli Research and Development Center LLC
Arecibo, Puerto Rico
Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Novartis Investigative Site
Sant Cugat Del V, Barcelona, Spain
Novartis Investigative Site
Burjassot, Valencia, Spain
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
Bristol, United Kingdom
Novartis Investigative Site
London, United Kingdom